SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Core Viewpoint - SAB Biotherapeutics, Inc. is advancing its lead program, SAB-142, a human anti-thymocyte immunoglobulin aimed at treating type 1 diabetes (T1D) and other autoimmune diseases, with presentations scheduled at the ATTD-Asia conference in Singapore [1][2]. Group 1: Company Overview - SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency immunotherapies [5]. - The company utilizes advanced genetic engineering and antibody science to create therapeutic candidates without relying on human donors or convalescent plasma [6]. Group 2: Product Development - SAB-142 is in Phase 2b clinical development, targeting the delay of T1D progression in new-onset, Stage 3 patients [2][4]. - The mechanism of action of SAB-142 involves modulating immune cells that attack pancreatic beta cells, potentially preserving insulin production [4]. Group 3: Conference Presentations - The company will present data on SAB-142's mechanism of action and safety profile at the ATTD-Asia conference, with specific presentations scheduled for December 10, 2025 [3]. - Presentations will include discussions on immunomodulation without sustained lymphodepletion and the safety profile of SAB-142 [3].